The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ArticleNo Access

THE TREATMENT OF PARKINSONISM WITH UK 738: A CLINICAL TRIAL

Published Online:https://doi.org/10.1176/ajp.119.6.534

These results show that UK 738 has only a very slight effect on the symptoms of naturally occuring parkinsonism, and it is not as effective as benzhexol. When compared with a dummy in a double blind trial, benzhexol itself is not outstandingly effective.

These results are very different from those obtained by May and his colleagues (3, 4) and although their cases were of phenothiazine induced parkinsonism, it is more likely that the discrepancy is due to their lack of control in the trial than to any difference in aetiology.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.